Hizentra
Biological
CSL Behring
Total Payments
$42.7M
Transactions
67,334
Doctors
10,941
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12.6M | 11,815 | 4,147 |
| 2023 | $13.2M | 10,436 | 3,782 |
| 2022 | $4.7M | 8,620 | 3,431 |
| 2021 | $4.1M | 7,439 | 2,763 |
| 2020 | $1.4M | 5,566 | 2,303 |
| 2019 | $2.8M | 9,202 | 3,141 |
| 2018 | $2.4M | 7,871 | 2,953 |
| 2017 | $1.7M | 6,385 | 2,034 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $36.3M | 3,114 | 84.8% |
| Honoraria | $2.6M | 928 | 6.2% |
| Food and Beverage | $1.5M | 58,970 | 3.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 676 | 3.0% |
| Travel and Lodging | $725,907 | 2,314 | 1.7% |
| Consulting Fee | $328,163 | 105 | 0.8% |
| Grant | $25,000 | 2 | 0.1% |
| Education | $21,123 | 1,224 | 0.0% |
| Gift | $416.10 | 1 | 0.0% |
Payments by Type
Research
$36.3M
3,114 transactions
General
$6.5M
64,220 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | CSL Behring | $31.0M | 8 |
| Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) | CSL Behring | $894,547 | 1 |
| Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra GoDisc Wearable Infusor and the Crono Pump | CSL Behring | $819,330 | 0 |
| Safety and Tolerability of Higher Infusion Parameters of IgPro20 Hizentra in Subjects With Primary Immunodeficiency PID | CSL Behring | $808,340 | 0 |
| Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) | CSL Behring | $785,156 | 0 |
| A prospective case series of subcutaneous immunoglobulin for prophylaxis of infections in patients with chronic lymphocytic leukemia with impaired humoral immunity | CSL Behring | $459,200 | 0 |
| A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency in Patients with Potentially Reversible Airway Disease | CSL Behring | $405,721 | 0 |
| A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency in Patients With Potentially Reversible Airway Disease | CSL Behring | $226,947 | 0 |
| A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen) for the Treatment of Adults With Systemic Sclerosis | CSL Behring | $225,680 | 0 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis DM | CSL Behring | $158,355 | 0 |
| Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | CSL Behring | $148,922 | 0 |
| Comparison of 2 Infusion Devices with Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | CSL Behring | $136,533 | 0 |
| A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity | CSL Behring | $54,880 | 0 |
| Safety and Efficacy of Hizentra in Pediatric Hematopoietic Stem Cell Recipients | CSL Behring | $42,790 | 0 |
| Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin IgPro20, Hizentra on Weekly and Biweekly Schedules | CSL Behring | $22,580 | 0 |
| A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy | CSL Behring | $13,720 | 0 |
| Chronic Inflammatory Demyelinating Polyneuropathy CIDP and Treatment With Subcutaneous Immunoglobulin IgPro20 | CSL Behring | $12,812 | 0 |
| Double-blind, Randomized, Placebo-Controlled, Prospective Phase 3 Study Evaluating Efficacy, Safety, and Pharmacokinetics of IgPro20 as Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia and Hypogammaglobulinemia | CSL Behring | $8,000 | 0 |
| Comparison of 2 Infusion Devices with Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | CSL Behring | $2,615 | 0 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics ofIgPro20(Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study | CSL Behring | $2,584 | 0 |
Top Doctors Receiving Payments for Hizentra — Page 438
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | Livingston, NJ | $10.70 | 1 |
| , M.D | Allergy | Chapel Hill, NC | $10.70 | 1 |
| , M.D | Neonatal-Perinatal Medicine | Omaha, NE | $10.70 | 1 |
| , MD | Allergy & Immunology | Berwyn, PA | $10.70 | 1 |
| , M.D | Obstetrics & Gynecology | Keene, NH | $10.70 | 1 |
| , MD | Hematology & Oncology | Glasgow, KY | $10.62 | 1 |
| , M.D | Nephrology | Santa Barbara, CA | $10.59 | 1 |
| , M.D | Internal Medicine | Mission Viejo, CA | $10.58 | 1 |
| , MD | Neurology | Syracuse, NY | $10.53 | 1 |
| Purva Gumaste | Infectious Disease | Grand Island, NE | $10.42 | 1 |
| , MD | Allergy | Saint Paul, MN | $10.33 | 1 |
| , PA | Specialist | Highlands Ranch, CO | $8.92 | 1 |
| , MSN, CPNP, FNP | Allergy | Las Vegas, NV | $5.69 | 1 |
| , MD | Allergy & Immunology | Las Vegas, NV | $5.69 | 1 |
| , M.D | Allergy | Henderson, NV | $5.69 | 1 |
| , MD | Pulmonary Disease | Marietta, GA | $5.62 | 1 |
| , MD | Allergy & Immunology | Saint Paul, MN | $5.16 | 1 |
Ad
Manufacturing Companies
- CSL Behring $42.7M
Product Information
- Type Biological
- Total Payments $42.7M
- Total Doctors 10,941
- Transactions 67,334
About Hizentra
Hizentra is a biological associated with $42.7M in payments to 10,941 healthcare providers, recorded across 67,334 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $12.6M was paid across 11,815 transactions to 4,147 doctors.
The most common payment nature for Hizentra is "Unspecified" ($36.3M, 84.8% of total).
Hizentra is associated with 20 research studies, including "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM)" ($31.0M).